State of the art: medical treatment of Peyronie's disease

Sicard K. G., Aliperti L. A., USTA M. F., Hellstrom W. J. G.

EXPERT OPINION ON ORPHAN DRUGS, cilt.1, sa.11, ss.867-876, 2013 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 1 Sayı: 11
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1517/21678707.2013.851026
  • Dergi Adı: EXPERT OPINION ON ORPHAN DRUGS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.867-876
  • Anahtar Kelimeler: erectile dysfunction, oral therapies, Peyronie's disease, sexual dysfunction, COLLAGENASE CLOSTRIDIUM-HISTOLYTICUM, PROPIONYL-L-CARNITINE, INTRALESIONAL INTERFERON-ALPHA-2B, DOUBLE-BLIND, TUNICA ALBUGINEA, LOCAL INTERFERON-ALPHA-2B, NONSURGICAL TREATMENT, SEXUAL DYSFUNCTIONS, CLINICAL-EFFICACY, SINGLE-BLIND
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Introduction: Peyronie's disease (PD) is a wound-healing disorder of the penis and is estimated to affect 3 - 9% of men. Once believed to be a spontaneously resolving condition, it is now established that most cases of PD progress. The pathophysiology of PD involves the formation of collagenous plaques within the tunica albuginea with subsequent development of penile curvature or indentations of the penis. This may evolve into pain with erection and difficulty with intromission. PD follows a predictable natural history consisting of an acute phase characterized by progressive plaque formation with sometimes painful erections and a chronic phase in which plaques stabilize. Men with PD are hypothesized to have a genetic predisposition that causes abnormal wound healing, and some antecedent penile (micro) trauma, usually precipitated by sexual intercourse.